Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1981 3
1982 6
1983 3
1984 5
1985 14
1986 20
1987 39
1988 44
1989 69
1990 77
1991 106
1992 117
1993 142
1994 152
1995 207
1996 182
1997 184
1998 190
1999 253
2000 293
2001 297
2002 291
2003 307
2004 314
2005 301
2006 272
2007 292
2008 323
2009 361
2010 364
2011 426
2012 414
2013 400
2014 468
2015 476
2016 429
2017 484
2018 544
2019 215
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

8,357 results
Results by year
Filters applied: . Clear all
Page 1
A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
Bilal J, et al. J Dermatolog Treat 2018 - Review. PMID 29532693
OBJECTIVE: To systematically analyze the efficacy and safety of interleukin (IL)-12/23, IL-17, and selective IL-23 inhibitors in moderate to severe plaque psoriasis. ...
OBJECTIVE: To systematically analyze the efficacy and safety of interleukin (IL)-12/23, IL-17, and selective IL-23 inhibitors
Safety of biologics in psoriasis
Kamata M and Tada Y. J Dermatol 2018 - Review. PMID 29226369
Two tumor necrosis factor-α inhibitors; infliximab and adalimumab, one anti-interleukin (IL)-12/23p40 antibody; ustekinumab, and IL-17 inhibitors; secukinumab, ixekizumab and brodalumab. ...
Two tumor necrosis factor-α inhibitors; infliximab and adalimumab, one anti-interleukin (IL)-12/23p40 antibody; ustekinumab, a …
New treatment options for inflammatory bowel diseases
Verstockt B, et al. J Gastroenterol 2018 - Review. PMID 29556726 Free PMC article.
Tofacitinib, a non-selective oral Janus kinase (JAK) inhibitor, is effective in patients with UC and several other more or less selective Jak1, 2 and 3 inhibitors are being developed for the treatment of CD and UC (Sandborn et al. in N Engl J Med 376(18):1723-1736, 2017; Vermeire et al. in Lancet 389(10066):266-275, 2017; De Vries et al. in J Crohns Colitis 11(7):885-93, 2017). ...
Tofacitinib, a non-selective oral Janus kinase (JAK) inhibitor, is effective in patients with UC and several other more or less selective Ja …
New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
Dong J and Goldenberg G. Cutis 2017 - Review. PMID 28319618
In this article, we review the literature on IL-23 and IL-17 inhibitors in the pipeline for use in moderate to severe psoriasis. ...
In this article, we review the literature on IL-23 and IL-17 inhibitors in the pipeline for use in moderate to severe psoriasis. ...
Role of interleukin-6 in cancer progression and therapeutic resistance.
Kumari N, et al. Tumour Biol 2016 - Review. PMID 27260630
Interleukin-6 (IL-6), one of the major cytokines in the tumour microenvironment, is an important factor which is found at high concentrations and known to be deregulated in cancer. ...
Interleukin-6 (IL-6), one of the major cytokines in the tumour microenvironment, is an important factor which is found at high concen
Biological treatments for severe asthma: A major advance in asthma care
Busse WW. Allergol Int 2019 - Review. PMID 30792118 Free article.
T2 high is characterized by the generation of key cytokines, interleukin (IL)-4, -5 and -13, which generate and regulate airway inflammation. ...
T2 high is characterized by the generation of key cytokines, interleukin (IL)-4, -5 and -13, which generate and regulate airway infla …
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Papp KA, et al. N Engl J Med 2017 - Clinical Trial. PMID 28423301 Free article.
BACKGROUND: Interleukin-23 is thought to be critical to the pathogenesis of psoriasis. We compared risankizumab (BI 655066), a humanized IgG1 monoclonal antibody that inhibits interleukin-23 by specifically targeting the p19 subunit and thus prevents interleukin-23 signaling, and ustekinumab, an interleukin-12 and interleukin-23 inhibitor, in patients with moderate-to-severe plaque psoriasis. ...CONCLUSIONS: In this phase 2 trial, selective blockade of interleukin-23 with risankizumab was associated with clinical responses superior to those associated with ustekinumab. ...
BACKGROUND: Interleukin-23 is thought to be critical to the pathogenesis of psoriasis. We compared risankizumab (BI 655066), a humani …
Emerging therapies in psoriasis: a systematic review
Lee EB, et al. Cutis 2018 - Review. PMID 29718027
We reviewed published data from phase 2 and 3 clinical trials of 2 IL-17 inhibitors (ixekizumab and brodalumab); 3 IL-23 inhibitors (guselkumab, tildrakizumab, and risankizumab); and 1 tumor necrosis factor (TNF) inhibitor (certolizumab pegol). Janus kinase inhibitors were not included in our review, as they currently are not approved by the US Food and Drug Administration (FDA) and there are no plans to further develop this class for treatment of psoriasis. ...
We reviewed published data from phase 2 and 3 clinical trials of 2 IL-17 inhibitors (ixekizumab and brodalumab); 3 IL-23 inhibitor
Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease.
Deepak P and Sandborn WJ. Gastroenterol Clin North Am 2017 - Review. PMID 28838418
This article reviews the available data regarding the efficacy of ustekinumab across published randomized clinical trials and open-label experience from tertiary medical centers, safety data, including in pregnancy, and its use in patients who have failed tumor necrosis factor (TNF) antagonists as well as patients who have not failed TNF antagonists. ...The article also enumerates drugs that are specific interleukin-23 blockers, including brazikumab (MEDI2070), risankizumab, LY3074828, tildrakizumab, and guselkumab, and the current status of their clinical trials....
This article reviews the available data regarding the efficacy of ustekinumab across published randomized clinical trials and open-label exp …
Dupilumab for Moderate-to-Severe Atopic Dermatitis
Vangipuram R and Tyring SK. Skin Therapy Lett 2017 - Review. PMID 29091379 Free article.
Dupilumab, an interleukin (IL)-4 and IL-13 antagonist that limits type 2 T helper (Th2) driven inflammatory activity, is a promising therapeutic option. ...
Dupilumab, an interleukin (IL)-4 and IL-13 antagonist that limits type 2 T helper (Th2) driven inflammatory activity, is a pro …
8,357 results
Jump to page
Feedback